A new publication using BÜHLMANN Quantum Blue® fCAL is looking at the impact of using fecal Calprotectin in IBD management . Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211.PMID:27688663. “The FC test effected a change in management 51.3% of the time and
- info@buhlmannlabs.ch
- +41 61 487 12 12
Blog Archives
New BÜHLMANN fCAL® turbo publication Nilsen, T. et. al. A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers. J Clin Lab Anal. 2016 Sep 15. PMID:27629827 The publication describes the technical performance of the turbidimetric assay on the cobas c501 and the Mindray BS-380. Highlights from this Publication: Short assay time of 10 min with
Flow CAST® - Kinase Inhibtion Assay Citation: Lannutti, B.J. et al. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011 Jan 13; 117(2): 591-594. PMID: 20959606. "We have thus described the biochemical and cellular activity of CAL-101, a selective and potent inhibitor of p110δ; such targeted
Continue Reading →
Social Links